Results 31 to 40 of about 131,732 (302)
Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition [PDF]
, 2011 Background LINE-1s (L1, Long Interspersed Element-1) are the most abundant autonomous non-LTR retrotransposons in the human genome and replicate by reverse transcription of an RNA intermediate.
Qing Huang, Jef D Boeke, Lixin Dai
core +1 more source
PLoS ONE, 2020 BackgroundChoice of initial antiretroviral therapy regimen may help children with HIV maintain optimal, continuous therapy. We assessed treatment-naïve children for differences in time to treatment disruption across randomly-assigned protease inhibitor ...
Dwight E Yin +7 more
doaj +1 more source
Viruses, 2023 Tenofovir disoproxil fumarate (TDF) and islatravir (ISL, 4′-ethynyl-2-fluoro-2′-deoxyadensine, or MK-8591) are highly potent nucleoside reverse transcriptase inhibitors. Resistance to TDF and ISL is conferred by K65R and M184V, respectively. Furthermore,
Maria E. Cilento +14 more
doaj +1 more source
Discovery of non-nucleoside inhibitors of HIV-1 reverse transcriptase competing with the nucleotide substrate [PDF]
, 2022 How odd! A new class of non-nucleoside reverse transcriptase inhibitors with a 6-vinylpyrimidine scaffold (1) has been found to inhibit HIV-1 reverse transcriptase (RT) by competition with the nucleotide substrate after binding to the non-nucleoside ...
Maga, Giovanni +10 more
core +3 more sources
The “Connection” Between HIV Drug Resistance and RNase H
Viruses, 2010 Currently, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are two classes of antiretroviral agents that are approved for treatment of HIV-1 infection. Since both NRTIs and NNRTIs target the
Krista A. Delviks-Frankenberry +2 more
doaj +1 more source
Reverse transcriptase inhibition: a way to defeat HIV
HIV & AIDS Review. International Journal of HIV-Related Problems, 2022 Human immunodeficiency virus (HIV) induces disease in humans that is known as AIDS (acquired immunodeficiency syndrome). First AIDS cases were registered in 1981, and later, types of HIV infection, such as HIV-1 and HIV-2 were identified.
Vikas Kumar, Harish Joshi, I. Pandey
doaj +1 more source
Chemical structures of the studied non-nucleoside reverse transcriptase inhibitors. [PDF]
, 2015 Chemical structures of the studied non-nucleoside reverse transcriptase inhibitors.
Markus Hecht (757364) +8 more
core +1 more source
Selected Milestones in Antiviral Drug Development
VirusesThis review article will describe the (wide) variety of approaches that I envisaged to develop a specific therapy for viral infections: (i) interferon and its inducers, (ii) HSV, VZV and CMV inhibitors, (iii) NRTIs (nucleoside reverse transcriptase ...
Erik De Clercq
doaj +1 more source
Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism
Brazilian Journal of Pharmaceutical Sciences, 2011 From the identification of HIV as the agent causing AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research over the past twenty-six years have been formidable.
Carolina Horta Andrade +2 more
doaj +1 more source
Future of nonnucleoside reverse transcriptase inhibitors [PDF]
Proceedings of the National Academy of Sciences, 2018 The nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are small molecules that bind to HIV-1 RT at a site distinct from the DNA polymerase active site of the enzyme and block retroviral reverse transcription via an allosteric mechanism of action (1). Nevirapine (NVP) was the first NNRTI approved in 1996 by the US Food and Drug Administration
openaire +2 more sources